RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Nazarius Lamango to Humans

This is a "connection" page, showing publications Nazarius Lamango has written about Humans.
Connection Strength

0.342
  1. Lazarte JMS, Ofosu-Asante K, Tilghman SL, Lamango NS. PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion. Oncotarget. 2025 Jul 29; 16:621-641.
    View in: PubMed
    Score: 0.043
  2. Gregory MD, Ofosu-Asante K, Lazarte JMS, Puente PE, Tawfeeq N, Belony N, Huang Y, Offringa IA, Lamango NS. Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis. PLoS One. 2024; 19(10):e0312563.
    View in: PubMed
    Score: 0.040
  3. Tawfeeq N, Lazarte JMS, Jin Y, Gregory MD, Lamango NS. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines. Oncotarget. 2023 03 24; 14:243-257.
    View in: PubMed
    Score: 0.036
  4. Lamango NS, Nkembo AT, Ntantie E, Tawfeeq N. Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling. Curr Med Chem. 2021; 28(18):3476-3489.
    View in: PubMed
    Score: 0.031
  5. Nkembo AT, Amissah F, Ntantie E, Poku RA, Salako OO, Ikpatt OF, Lamango NS. Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells. Curr Cancer Drug Targets. 2019; 19(10):838-851.
    View in: PubMed
    Score: 0.027
  6. Ntantie E, Fletcher J, Amissah F, Salako OO, Nkembo AT, Poku RA, Ikpatt FO, Lamango NS. Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer. Oncotarget. 2017 May 09; 8(19):31726-31744.
    View in: PubMed
    Score: 0.024
  7. Nkembo AT, Ntantie E, Salako OO, Amissah F, Poku RA, Latinwo LM, Lamango NS. The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget. 2016 Oct 18; 7(42):68194-68205.
    View in: PubMed
    Score: 0.023
  8. Aguilar BJ, Nkembo AT, Duverna R, Poku RA, Amissah F, Ablordeppey SY, Lamango NS. Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer. Eur J Med Chem. 2014 Jun 23; 81:323-33.
    View in: PubMed
    Score: 0.020
  9. Amissah F, Duverna R, Aguilar BJ, Poku RA, Lamango NS. Polyisoprenylated methylated protein methyl esterase is both sensitive to curcumin and overexpressed in colorectal cancer: implications for chemoprevention and treatment. Biomed Res Int. 2013; 2013:416534.
    View in: PubMed
    Score: 0.018
  10. Ayuk-Takem L, Amissah F, Aguilar BJ, Lamango NS. Inhibition of polyisoprenylated methylated protein methyl esterase by synthetic musks induces cell degeneration. Environ Toxicol. 2014 Apr; 29(4):466-77.
    View in: PubMed
    Score: 0.017
  11. Aguilar B, Amissah F, Duverna R, Lamango NS. Polyisoprenylation potentiates the inhibition of polyisoprenylated methylated protein methyl esterase and the cell degenerative effects of sulfonyl fluorides. Curr Cancer Drug Targets. 2011 Jul; 11(6):752-62.
    View in: PubMed
    Score: 0.016
  12. Duverna R, Ablordeppey SY, Lamango NS. Biochemical and docking analysis of substrate interactions with polyisoprenylated methylated protein methyl esterase. Curr Cancer Drug Targets. 2010 Sep; 10(6):634-48.
    View in: PubMed
    Score: 0.015
  13. Reams RR, Odedina FT, Carpten JD, Redda K, Stern MC, Krieger JL, Aparicio J, Hensel B, Askins N, Abreu A, Adams A, Agyare E, Ali J, Allen JM, Al? R, Baezconde-Garbanati L, Brant J, Brown CP, Buxbaum SG, Cohen P, Cozen W, Ezenwa MO, Falzarano S, Fillingim RB, Flores-Rozas H, Fredenburg KM, George T, Han B, Huang Y, Hughes Halbert C, Kiros GE, Lamango NS, Lee JH, Lyon DE, Mitchell DA, Mochona B, Nieva JJ, Offringa IA, Okunieff P, Parker A, Rhie SK, Richey JM, Rogers SC, Salhia B, Schmittgen TD, Segal R, Setiawan VW, Smith U, Su LM, Suther S, Trevino J, Velazquez-Villarreal EI, Webb FJ, Wu AH, Yao Y, Wilkie DJ. Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center: Structure, Innovations, and Initial Outcomes. Cancer Control. 2023 Jan-Dec; 30:10732748231197878.
    View in: PubMed
    Score: 0.009
  14. Asong G, Zhu XY, Bricker B, Andey T, Amissah F, Lamango N, Ablordeppey SY. New analogs of SYA013 as sigma-2 ligands with anticancer activity. Bioorg Med Chem. 2019 06 15; 27(12):2629-2636.
    View in: PubMed
    Score: 0.007
  15. Lamango NS, Zhu X, Lindberg I. Purification and enzymatic characterization of recombinant prohormone convertase 2: stabilization of activity by 21 kDa 7B2. Arch Biochem Biophys. 1996 Jun 15; 330(2):238-50.
    View in: PubMed
    Score: 0.006
  16. Sampson D, Zhu XY, Eyunni SV, Etukala JR, Ofori E, Bricker B, Lamango NS, Setola V, Roth BL, Ablordeppey SY. Identification of a new selective dopamine D4 receptor ligand. Bioorg Med Chem. 2014 Jun 15; 22(12):3105-14.
    View in: PubMed
    Score: 0.005
  17. Shepherd KR, Lee ES, Schmued L, Jiao Y, Ali SF, Oriaku ET, Lamango NS, Soliman KF, Charlton CG. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Pharmacol Biochem Behav. 2006 Mar; 83(3):349-59.
    View in: PubMed
    Score: 0.003
  18. Zhu X, Rouille Y, Lamango NS, Steiner DF, Lindberg I. Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2: a potential mechanism for its inactivation. Proc Natl Acad Sci U S A. 1996 May 14; 93(10):4919-24.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support